Elevation of C-reactive protein during concurrent chemoradiotherapy is a poor predictive factor for head and neck cancer

The prognostic role of pretreatment C-reactive protein (CRP) has been reported for head and neck cancer. However, little is known about the relationship between the changes in CRP levels during treatment and prognosis. This study aimed to investigate the correlation between CRP elevation during conc...

Full description

Saved in:
Bibliographic Details
Published in:Auris, nasus, larynx nasus, larynx, 2023-08, Vol.50 (4), p.601-606
Main Authors: Adachi, Masahiro, Nakayama, Masahiro, Matsumoto, Shin, Shima, Yoshihide, Uemaetomari, Isao, Yoshimura, Tomonori, Onishi, Kayoko, Senarita, Masamitsu, Tabuchi, Keiji
Format: Article
Language:English
Subjects:
C-reactive protein
Concurrent chemoradiotherapy
Head and neck cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c420t-c0943c232136fb08b55c919ef3254f314804528a975466546f345098508159693
cites cdi_FETCH-LOGICAL-c420t-c0943c232136fb08b55c919ef3254f314804528a975466546f345098508159693
container_end_page 606
container_issue 4
container_start_page 601
container_title Auris, nasus, larynx
container_volume 50
creator Adachi, Masahiro
Nakayama, Masahiro
Matsumoto, Shin
Shima, Yoshihide
Uemaetomari, Isao
Yoshimura, Tomonori
Onishi, Kayoko
Senarita, Masamitsu
Tabuchi, Keiji
description The prognostic role of pretreatment C-reactive protein (CRP) has been reported for head and neck cancer. However, little is known about the relationship between the changes in CRP levels during treatment and prognosis. This study aimed to investigate the correlation between CRP elevation during concurrent chemoradiotherapy (CCRT) and survival outcomes. The medical records of patients with oropharyngeal, hypopharyngeal, and laryngeal cancer treated with CCRT at the University of Tsukuba Hospital and National Hospital Organization Mito Medical Center from April 2014 to December 2019 were retrospectively reviewed. Patients were divided into normal (
doi_str_mv 10.1016/j.anl.2022.12.014
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2761976333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0385814622002413</els_id><sourcerecordid>2761976333</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-c0943c232136fb08b55c919ef3254f314804528a975466546f345098508159693</originalsourceid><addsrcrecordid>eNp9kM1qGzEUhUVpaBynD9BN0bKbmeh_RnRVTP4gkE2yFrLmqpY7llxpxtRvXxknXVZwEVzO-eB-CH2hpKWEqptta-PYMsJYS1lLqPiAFrTvdENFpz6iBeG9bHoq1CW6KmVLCOEd15_QJVeKCCb1Av25HeFgp5AiTh6vmgzWTeEAeJ_TBCHiYc4h_sQuRTfnDHHCbgO7lO0Q0rSBbPdHHAq2eJ9Sri0YwhngK6hufJ0N2AHbOOAI7hd2NjrI1-jC27HA57d_iV7vbl9WD83T8_3j6sdT4wQjU-OIFtwxzihXfk36tZROUw2eMyk8p6InQrLe6k4Kpep4LiTRvSQ9lVppvkTfztx60O8ZymR2oTgYRxshzcWwTlHdKV7fEtFz1OVUSgZv9jnsbD4aSsxJuNmaKtychBvKTBVeO1_f8PN6B8O_xrvhGvh-DkA98hAgm-ICVANDyOAmM6TwH_xfWJSQHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2761976333</pqid></control><display><type>article</type><title>Elevation of C-reactive protein during concurrent chemoradiotherapy is a poor predictive factor for head and neck cancer</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Adachi, Masahiro ; Nakayama, Masahiro ; Matsumoto, Shin ; Shima, Yoshihide ; Uemaetomari, Isao ; Yoshimura, Tomonori ; Onishi, Kayoko ; Senarita, Masamitsu ; Tabuchi, Keiji</creator><creatorcontrib>Adachi, Masahiro ; Nakayama, Masahiro ; Matsumoto, Shin ; Shima, Yoshihide ; Uemaetomari, Isao ; Yoshimura, Tomonori ; Onishi, Kayoko ; Senarita, Masamitsu ; Tabuchi, Keiji</creatorcontrib><description>The prognostic role of pretreatment C-reactive protein (CRP) has been reported for head and neck cancer. However, little is known about the relationship between the changes in CRP levels during treatment and prognosis. This study aimed to investigate the correlation between CRP elevation during concurrent chemoradiotherapy (CCRT) and survival outcomes. The medical records of patients with oropharyngeal, hypopharyngeal, and laryngeal cancer treated with CCRT at the University of Tsukuba Hospital and National Hospital Organization Mito Medical Center from April 2014 to December 2019 were retrospectively reviewed. Patients were divided into normal (&lt;0.3 mg/dl) and elevated (≥0.3 mg/dl) CRP groups according to the CRP level after the first cycle of cisplatin. The primary endpoint was progression-free survival (PFS). A total of 74 patients were enrolled, of whom 36 (49%) showed elevated CRP levels after the first cycle of cisplatin. The 3-year PFS was 83.3% and 61.0% in the normal and elevated CRP groups, respectively, showing significant differences between the two groups. Elevated CRP levels after the first cycle of cisplatin is an objective predictive marker for survival in patient with head and neck squamous cell carcinoma treated with CCRT.</description><identifier>ISSN: 0385-8146</identifier><identifier>EISSN: 1879-1476</identifier><identifier>DOI: 10.1016/j.anl.2022.12.014</identifier><identifier>PMID: 36604259</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>C-reactive protein ; Concurrent chemoradiotherapy ; Head and neck cancer</subject><ispartof>Auris, nasus, larynx, 2023-08, Vol.50 (4), p.601-606</ispartof><rights>2023</rights><rights>Copyright © 2023. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-c0943c232136fb08b55c919ef3254f314804528a975466546f345098508159693</citedby><cites>FETCH-LOGICAL-c420t-c0943c232136fb08b55c919ef3254f314804528a975466546f345098508159693</cites><orcidid>0000-0001-6489-446X ; 0000-0003-0942-8655 ; 0000-0001-9285-7877 ; 0000-0002-6497-5099</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36604259$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adachi, Masahiro</creatorcontrib><creatorcontrib>Nakayama, Masahiro</creatorcontrib><creatorcontrib>Matsumoto, Shin</creatorcontrib><creatorcontrib>Shima, Yoshihide</creatorcontrib><creatorcontrib>Uemaetomari, Isao</creatorcontrib><creatorcontrib>Yoshimura, Tomonori</creatorcontrib><creatorcontrib>Onishi, Kayoko</creatorcontrib><creatorcontrib>Senarita, Masamitsu</creatorcontrib><creatorcontrib>Tabuchi, Keiji</creatorcontrib><title>Elevation of C-reactive protein during concurrent chemoradiotherapy is a poor predictive factor for head and neck cancer</title><title>Auris, nasus, larynx</title><addtitle>Auris Nasus Larynx</addtitle><description>The prognostic role of pretreatment C-reactive protein (CRP) has been reported for head and neck cancer. However, little is known about the relationship between the changes in CRP levels during treatment and prognosis. This study aimed to investigate the correlation between CRP elevation during concurrent chemoradiotherapy (CCRT) and survival outcomes. The medical records of patients with oropharyngeal, hypopharyngeal, and laryngeal cancer treated with CCRT at the University of Tsukuba Hospital and National Hospital Organization Mito Medical Center from April 2014 to December 2019 were retrospectively reviewed. Patients were divided into normal (&lt;0.3 mg/dl) and elevated (≥0.3 mg/dl) CRP groups according to the CRP level after the first cycle of cisplatin. The primary endpoint was progression-free survival (PFS). A total of 74 patients were enrolled, of whom 36 (49%) showed elevated CRP levels after the first cycle of cisplatin. The 3-year PFS was 83.3% and 61.0% in the normal and elevated CRP groups, respectively, showing significant differences between the two groups. Elevated CRP levels after the first cycle of cisplatin is an objective predictive marker for survival in patient with head and neck squamous cell carcinoma treated with CCRT.</description><subject>C-reactive protein</subject><subject>Concurrent chemoradiotherapy</subject><subject>Head and neck cancer</subject><issn>0385-8146</issn><issn>1879-1476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kM1qGzEUhUVpaBynD9BN0bKbmeh_RnRVTP4gkE2yFrLmqpY7llxpxtRvXxknXVZwEVzO-eB-CH2hpKWEqptta-PYMsJYS1lLqPiAFrTvdENFpz6iBeG9bHoq1CW6KmVLCOEd15_QJVeKCCb1Av25HeFgp5AiTh6vmgzWTeEAeJ_TBCHiYc4h_sQuRTfnDHHCbgO7lO0Q0rSBbPdHHAq2eJ9Sri0YwhngK6hufJ0N2AHbOOAI7hd2NjrI1-jC27HA57d_iV7vbl9WD83T8_3j6sdT4wQjU-OIFtwxzihXfk36tZROUw2eMyk8p6InQrLe6k4Kpep4LiTRvSQ9lVppvkTfztx60O8ZymR2oTgYRxshzcWwTlHdKV7fEtFz1OVUSgZv9jnsbD4aSsxJuNmaKtychBvKTBVeO1_f8PN6B8O_xrvhGvh-DkA98hAgm-ICVANDyOAmM6TwH_xfWJSQHw</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Adachi, Masahiro</creator><creator>Nakayama, Masahiro</creator><creator>Matsumoto, Shin</creator><creator>Shima, Yoshihide</creator><creator>Uemaetomari, Isao</creator><creator>Yoshimura, Tomonori</creator><creator>Onishi, Kayoko</creator><creator>Senarita, Masamitsu</creator><creator>Tabuchi, Keiji</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6489-446X</orcidid><orcidid>https://orcid.org/0000-0003-0942-8655</orcidid><orcidid>https://orcid.org/0000-0001-9285-7877</orcidid><orcidid>https://orcid.org/0000-0002-6497-5099</orcidid></search><sort><creationdate>202308</creationdate><title>Elevation of C-reactive protein during concurrent chemoradiotherapy is a poor predictive factor for head and neck cancer</title><author>Adachi, Masahiro ; Nakayama, Masahiro ; Matsumoto, Shin ; Shima, Yoshihide ; Uemaetomari, Isao ; Yoshimura, Tomonori ; Onishi, Kayoko ; Senarita, Masamitsu ; Tabuchi, Keiji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-c0943c232136fb08b55c919ef3254f314804528a975466546f345098508159693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>C-reactive protein</topic><topic>Concurrent chemoradiotherapy</topic><topic>Head and neck cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adachi, Masahiro</creatorcontrib><creatorcontrib>Nakayama, Masahiro</creatorcontrib><creatorcontrib>Matsumoto, Shin</creatorcontrib><creatorcontrib>Shima, Yoshihide</creatorcontrib><creatorcontrib>Uemaetomari, Isao</creatorcontrib><creatorcontrib>Yoshimura, Tomonori</creatorcontrib><creatorcontrib>Onishi, Kayoko</creatorcontrib><creatorcontrib>Senarita, Masamitsu</creatorcontrib><creatorcontrib>Tabuchi, Keiji</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Auris, nasus, larynx</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adachi, Masahiro</au><au>Nakayama, Masahiro</au><au>Matsumoto, Shin</au><au>Shima, Yoshihide</au><au>Uemaetomari, Isao</au><au>Yoshimura, Tomonori</au><au>Onishi, Kayoko</au><au>Senarita, Masamitsu</au><au>Tabuchi, Keiji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevation of C-reactive protein during concurrent chemoradiotherapy is a poor predictive factor for head and neck cancer</atitle><jtitle>Auris, nasus, larynx</jtitle><addtitle>Auris Nasus Larynx</addtitle><date>2023-08</date><risdate>2023</risdate><volume>50</volume><issue>4</issue><spage>601</spage><epage>606</epage><pages>601-606</pages><issn>0385-8146</issn><eissn>1879-1476</eissn><abstract>The prognostic role of pretreatment C-reactive protein (CRP) has been reported for head and neck cancer. However, little is known about the relationship between the changes in CRP levels during treatment and prognosis. This study aimed to investigate the correlation between CRP elevation during concurrent chemoradiotherapy (CCRT) and survival outcomes. The medical records of patients with oropharyngeal, hypopharyngeal, and laryngeal cancer treated with CCRT at the University of Tsukuba Hospital and National Hospital Organization Mito Medical Center from April 2014 to December 2019 were retrospectively reviewed. Patients were divided into normal (&lt;0.3 mg/dl) and elevated (≥0.3 mg/dl) CRP groups according to the CRP level after the first cycle of cisplatin. The primary endpoint was progression-free survival (PFS). A total of 74 patients were enrolled, of whom 36 (49%) showed elevated CRP levels after the first cycle of cisplatin. The 3-year PFS was 83.3% and 61.0% in the normal and elevated CRP groups, respectively, showing significant differences between the two groups. Elevated CRP levels after the first cycle of cisplatin is an objective predictive marker for survival in patient with head and neck squamous cell carcinoma treated with CCRT.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>36604259</pmid><doi>10.1016/j.anl.2022.12.014</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-6489-446X</orcidid><orcidid>https://orcid.org/0000-0003-0942-8655</orcidid><orcidid>https://orcid.org/0000-0001-9285-7877</orcidid><orcidid>https://orcid.org/0000-0002-6497-5099</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0385-8146
ispartof Auris, nasus, larynx, 2023-08, Vol.50 (4), p.601-606
issn 0385-8146
1879-1476
language eng
recordid cdi_proquest_miscellaneous_2761976333
source ScienceDirect Freedom Collection 2022-2024
subjects C-reactive protein
Concurrent chemoradiotherapy
Head and neck cancer
title Elevation of C-reactive protein during concurrent chemoradiotherapy is a poor predictive factor for head and neck cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T01%3A20%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevation%20of%20C-reactive%20protein%20during%20concurrent%20chemoradiotherapy%20is%20a%20poor%20predictive%20factor%20for%20head%20and%20neck%20cancer&rft.jtitle=Auris,%20nasus,%20larynx&rft.au=Adachi,%20Masahiro&rft.date=2023-08&rft.volume=50&rft.issue=4&rft.spage=601&rft.epage=606&rft.pages=601-606&rft.issn=0385-8146&rft.eissn=1879-1476&rft_id=info:doi/10.1016/j.anl.2022.12.014&rft_dat=%3Cproquest_cross%3E2761976333%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c420t-c0943c232136fb08b55c919ef3254f314804528a975466546f345098508159693%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2761976333&rft_id=info:pmid/36604259&rfr_iscdi=true